title: Stem Cell Therapies in Clinical Trials: Progress and Challenges.
abstract: Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising from autologous or allogeneic transplants. Many cells administered show transient presence for a few days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some with early benefits to patients.
authors.affiliation: Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia. Electronic address: alan.trounson@hudson.org.au.
authors.forename: Alan
authors.initials: A
authors.lastname: Trounson
authors.affiliation: Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia.
authors.forename: Courtney
authors.initials: C
authors.lastname: McDonald
mesh_terms: D002986:Clinical Trials as Topic; D042783:Endothelial Cells / Q000637:transplantation; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D016850:Limbus Corneae / Q000166:cytology; D008107:Liver Diseases / Q000628:therapy; D045164:Mesenchymal Stem Cell Transplantation; D009203:Myocardial Infarction / Q000628:therapy; D058953:Neural Stem Cells / Q000637:transplantation; D010003:Osteoarthritis / Q000628:therapy; D010920:Placenta / Q000166:cytology; D039904:Pluripotent Stem Cells / Q000637:transplantation; D011247:Pregnancy; D044968:Regenerative Medicine; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000639:trends*; D020521:Stroke / Q000628:therapy; D017211:Treatment Failure